Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02363868 · ClinicalTrials.gov registry record
Healthcare Costs Among Patients With CML Receiving Dasatinib or Nilotinib in a Commercial and Medicare Population
A clinical trial of Chronic Myeloid Leukemia (CML), sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 186
- Enrollment target
- 1
- Study location
NCT02363868 is a study of Chronic Myeloid Leukemia (CML) that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 186 participants, above the 45-participant average among 7 other Chronic Myeloid Leukemia (CML) trials with a reported enrollment target (313% higher). The trial reports 1 study location across 1 state.
The verdict
NCT02363868, a study of Chronic Myeloid Leukemia (CML), has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 186 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to examine the healthcare costs among patients with CML receiving dasatinib or nilotinib as first line therapy in a commercially or Medicare insured population.
Conditions Studied
Study Locations (1)
South Carolina
- Franklin Pharmaceutical Consulting, Llc - Clinton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 186 participants |
| Start Date | 2014-02 |
| Est. Completion | 2014-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02363868
The ClinicalTrials.gov registry entry for NCT02363868 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 186 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 45-participant average among 7 other Chronic Myeloid Leukemia (CML) trials with a reported enrollment target (313% higher). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Myeloid Leukemia (CML) appearing as the primary indexed condition, and to 0 interventions.
NCT02363868 reports 1 study location spanning 1 distinct geographic area - top geographies include South Carolina.
Frequently Asked Questions
What is clinical trial NCT02363868 about?
NCT02363868 is a clinical study titled "Healthcare Costs Among Patients With CML Receiving Dasatinib or Nilotinib in a Commercial and Medicare Population". The purpose of this study is to examine the healthcare costs among patients with CML receiving dasatinib or nilotinib as first line therapy in a commercially or Medicare insured population.
What is the current status of trial NCT02363868?
This trial is currently completed. The enrollment target is 186 participants. The study started on 2014-02. Estimated completion is 2014-11.
What conditions does trial NCT02363868 study?
This clinical trial studies the following conditions: Chronic Myeloid Leukemia (CML).
Who is sponsoring clinical trial NCT02363868?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02363868 being conducted?
This trial has 1 study location across South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Myeloid Leukemia (CML)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
RECRUITING · Phase 1
-
CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant
ACTIVE NOT RECRUITING · Phase 1
-
TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies
ACTIVE NOT RECRUITING · Phase 2
-
Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation
ACTIVE NOT RECRUITING · Phase 2
-
Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers
COMPLETED · Phase 2
-
Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.